BioPharmSignal logoBioPharmSignal

Company Profile

Xenetic Stock Price, News & Catalysts

Ticker:
XBIO
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

2.46 USD (+12.33%)

Close

Last updated: September 17, 2026

7.74M USD

Market cap

Why the stock is moving

Following the latest company update, “Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics”, XBIO closed down 48.7% at $2.19 on Sep 16, 2026. The move occurred in the trading session associated with this company update.

Company overview

DNase Oncology Platform

Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance.

Tumor Microenvironment Strategy

The platform targets neutrophil extracellular traps and other DNA-rich components of the tumor microenvironment that may promote metastasis and suppress immune activity.

Translational Development

Xenetic is advancing investigator-sponsored research, biomarker work, manufacturing development, and clinical planning to establish the foundation for future oncology studies.

Future catalysts

    Recent news

    1. 01

      Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

    2. 02

      Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

    3. 03

      Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

    4. 04

      Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

    5. 05

      Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    ACHL

    Achilles Therapeutics

    ADAP

    Adaptimmune Therapeutics plc

    ACET

    Adicet Bio

    ALVR

    AlloVir

    ALLO

    Allogene Therapeutics

    ACLX

    Arcellx

    ATRA

    Atara Biotherapeutics, Inc.

    AUTL

    Autolus Therapeutics plc

    Frequently Asked Questions

    What is the current stock price of Xenetic (XBIO)?

    Xenetic (XBIO) most recently closed at 2.46 USD, a +12.33% move versus the previous session.

    What is the market cap of Xenetic (XBIO)?

    Xenetic currently has a market capitalization of 7.74M USD on BioPharmSignal.

    What does Xenetic do?

    DNase Oncology Platform Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance. Tumor Microenvironment Strategy The platform targets neutrophil extracellular traps and other DNA-rich components of the tumor microenvironment that may promote metastasis...

    On which exchange is XBIO stock listed?

    Xenetic (XBIO) is associated with NASDAQ, United States, Biopharma.

    What is DNase?

    DNase Oncology Platform Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance.

    Which conditions is Xenetic targeting with DNase?

    Xenetic is associated with oncology based on its company overview and current catalyst commentary.

    What is Oncology?

    DNase Oncology Platform Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance.

    What is Platform?

    DNase Oncology Platform Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance.